Q3 2025 Management View CEO Mihael Polymeropoulos reported "strong commercial execution with total net product sales reaching $56.3 million, up 18% year-over-year, led by a 31% increase in Fanapt ...

Mihael H. Polymeropoulos, CEO, highlighted continued commercial momentum, stating "During the second quarter, we continued the expansion of the Fanapt sales force and also continued our broad ...

Fanapt commercial growth has accelerated reaching multi year highs with weekly prescriptions surpassing 2,000 at the April as an increasing number of prescribers are adding Fanab to their therapeutic ...

This quarter reflects strong commercial execution with total net product sales reaching $56.3 million, up 18% year-over-year, ...

Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of ...

Fanapt is an atypical antipsychotic agent that has been used for the acute treatment of schizophrenia since its FDA approval in 2009. Vanda Pharmaceuticals' Hetlioz and Fanapt accounted for over 99% ...

Vanda Pharmaceuticals (VNDA) and marketing partner Novartis (NVS) announced the commercial launch of Vanda's schizophrenia drug Fanapt in early January, and this week Novartis released first quarter ...